- Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
- Tuninetti V, Ghisoni E, Pignata S, Picardo E, Raspagliesi F, Andreetta C, Maldi E, Artioli G, Mammoliti S, Zanchi L, Sikokis A, Biglia N, Parisi A, Mandato VD, Carella C, Cormio G, Marinaccio M, Puppo A, Paolini B, Borsotti L, Scotto G, Turinetto M, Sangiolo D, Di Maio M, Valabrega G.
- Cancers (Basel). 2023 Feb 6;15(4):1032. doi: 10.3390/cancers15041032.
- Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: JGOG3025 study.
- Yoshihara K, Baba T, Tokunaga H, Nishino K, Sekine M, Takamatsu S, Matsumura N, Yoshida H, Kajiyama H, Shimada M, Kagimura T, Oda K, Sasajima Y, Yaegashi N, Okamoto A, Sugiyama T, Enomoto T.
- Cancer Sci. 2023 Feb 6. doi: 10.1111/cas.15747. Epub ahead of print.
- PMID: 36747324
- PubMed abstract
- Source abstract
•• Identifier: NCT03159572: Homologous Recombination Inquiry Through Ovarian Malignancy Investigations (HITOMI). (ClinicalTrials.gov . Accessed 2023 Feb 7.)
- Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients.
- Jia B, Xia P, Dong J, Feng W, Wang W, Liu E, Jiang G, Qin Y.
- Front Oncol. 2023 Jan 17;12:1086908. doi: 10.3389/fonc.2022.1086908.
- PMID: 36741696
- PubMed abstract